Lincotek Names New Global General Manager for Medical Division
Lincotek Announces Appointment of New Global General Manager for Its Medical Division Lincotek has announced the appointment of Gianluca Fioravanti as Global General Manager of its Medical Division, marking a…
Virica Biotech and FUJIFILM Biosciences Partner to Advance AAV Production Enhancers Under Canada–Japan Program
Virica Biotech and FUJIFILM Biosciences Team Up to Advance AAV Production Enhancers Through Canada–Japan Co-Innovation Initiative Virica Biotech, a biotechnology firm focused on improving viral vector manufacturing through its proprietary…
Humana Inc. and CPESN USA Launch Value-Based Pharmacist Rewards Program to Enhance Chronic Care
Humana Inc. Healthy Horizons in Ohio and CPESN USA Introduce Value-Based Pharmacist Quality Rewards Program to Improve Chronic Disease Care Humana Inc., through its Medicaid plan Humana Healthy Horizons in…
Shionogi & Co., Ltd. Awarded U.S. Government Contract via BARDA Project BioShield for Drug-Resistant Bacterial Preparedness
Shionogi & Co., Ltd. Secures U.S. Government Contract via BARDA Project BioShield to Strengthen Preparedness Against Drug-Resistant Bacterial Threats Shionogi & Co., Ltd. has announced that its U.S.-based subsidiary, Shionogi…
Adagio Medical Receives U.S. Food and Drug Administration IDE Approval to Evaluate Next-Generation vCLAS® Ventricular Ablation System
Adagio Medical Secures U.S. Food and Drug Administration IDE Approval to Study Its Next-Generation vCLAS® Ventricular Ablation System Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio”), a medical technology company focused…
Cognito Therapeutics Partners with Initiative to Replace “Dementia” Terminology Across Communications
Cognito Therapeutics Collaborates with Initiative to Replace the “D-Word,” Committing to Remove “Dementia” from All Communications Cognito Therapeutics, a late clinical-stage neurotechnology company focused on developing non-invasive therapies for neurodegenerative…
ReAlta Life Sciences Secures $40M Financing to Advance Pegtarazimod Phase 2 Program in HIE
ReAlta Life Sciences Completes Oversubscribed $40M Financing to Support Pegtarazimod Phase 2 Development in Hypoxic Ischemic Encephalopathy (HIE) ReAlta Life Sciences Inc. (“ReAlta”), a clinical-stage biopharmaceutical company focused on targeting…
United Therapeutics Corporation Receives U.S. Food and Drug Administration RMAT Designation for miroliverELAP® in Acute Liver Failure
United Therapeutics Corporation Receives U.S. Food and Drug Administration Regenerative Medicine Advanced Therapy (RMAT) Designation for miroliverELAP® in the Treatment of Acute Liver Failure United Therapeutics Corporation (Nasdaq: UTHR), a…
Aurion Biotech Initiates Phase 3 ASTRA Study of AURN001 for Corneal Edema
Aurion Biotech Initiates Dosing in Phase 3 ASTRA Study Evaluating AURN001 for Corneal Edema Secondary to Corneal Endothelial Dysfunction Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company…
VION Biosciences Completes Acquisition of CTL to Enhance Functional Immune Monitoring Capabilities
VION Biosciences Completes Acquisition of CTL, Bolstering Its Functional Immune Monitoring Capabilities VION Biosciences (“VION”), a life sciences company focused on building differentiated capabilities across research, diagnostics, and drug development…
Sidewinder Therapeutics Secures $137M Series B to Advance Bispecific ADCs in Cancer Development
Sidewinder Therapeutics Secures $137 Million Series B to Advance Precision Bispecific ADCs into Clinical Development for Cancer Sidewinder Therapeutics, a biopharmaceutical company focused on advancing next-generation antibody-drug conjugates (ADCs) for…
Merck Initiates Tender Offer for the Acquisition of Terns Pharmaceuticals, Inc.
Merck Launches Tender Offer to Acquire Terns Pharmaceuticals, Inc. Merck & Co., Inc., known as MSD outside the United States and Canada, has officially launched a cash tender offer through…